Antonia Elizabeth Stephen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parathyroidectomy | 5 | 2019 | 244 | 1.790 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2021 | 164 | 1.710 |
Why?
|
| Thyroidectomy | 12 | 2021 | 912 | 1.680 |
Why?
|
| Thyroid Diseases | 6 | 2019 | 385 | 1.160 |
Why?
|
| Four-Dimensional Computed Tomography | 3 | 2021 | 140 | 1.110 |
Why?
|
| Thyroid Neoplasms | 15 | 2020 | 2354 | 1.060 |
Why?
|
| Parathyroid Neoplasms | 4 | 2016 | 244 | 1.040 |
Why?
|
| Parathyroid Glands | 3 | 2021 | 521 | 0.940 |
Why?
|
| Adrenalectomy | 4 | 2022 | 344 | 0.810 |
Why?
|
| Hyperparathyroidism | 3 | 2017 | 338 | 0.790 |
Why?
|
| Graves Disease | 3 | 2021 | 239 | 0.770 |
Why?
|
| Adenoma | 6 | 2016 | 2155 | 0.680 |
Why?
|
| Hypocalcemia | 2 | 2020 | 205 | 0.570 |
Why?
|
| Thyroid Nodule | 7 | 2020 | 765 | 0.550 |
Why?
|
| Technetium Tc 99m Sestamibi | 4 | 2021 | 185 | 0.550 |
Why?
|
| Biopsy, Fine-Needle | 9 | 2020 | 1130 | 0.490 |
Why?
|
| Testicular Hormones | 4 | 2002 | 188 | 0.460 |
Why?
|
| Thyroid Gland | 6 | 2020 | 1168 | 0.450 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 2022 | 453 | 0.440 |
Why?
|
| Growth Inhibitors | 4 | 2002 | 375 | 0.430 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 397 | 0.430 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2020 | 731 | 0.420 |
Why?
|
| Parathyroid Hormone | 3 | 2016 | 1790 | 0.410 |
Why?
|
| Adenocarcinoma, Follicular | 4 | 2020 | 323 | 0.400 |
Why?
|
| Pheochromocytoma | 1 | 2014 | 326 | 0.380 |
Why?
|
| Disease Management | 1 | 2021 | 2530 | 0.350 |
Why?
|
| Paraganglioma | 1 | 2011 | 142 | 0.330 |
Why?
|
| Calcium | 3 | 2019 | 5769 | 0.320 |
Why?
|
| Hyperthyroidism | 1 | 2010 | 292 | 0.310 |
Why?
|
| Quality Improvement | 2 | 2020 | 3847 | 0.290 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2011 | 340 | 0.290 |
Why?
|
| Decision Making | 1 | 2021 | 3955 | 0.280 |
Why?
|
| Preoperative Care | 4 | 2015 | 2248 | 0.280 |
Why?
|
| Glycoproteins | 4 | 2002 | 2196 | 0.280 |
Why?
|
| Hypoparathyroidism | 2 | 2020 | 136 | 0.260 |
Why?
|
| Postoperative Complications | 9 | 2020 | 15802 | 0.240 |
Why?
|
| Carcinoma, Papillary | 4 | 2016 | 786 | 0.240 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 2701 | 0.240 |
Why?
|
| Parathyroid Diseases | 2 | 2019 | 46 | 0.230 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2004 | 123 | 0.220 |
Why?
|
| Ultrasonography | 7 | 2021 | 5987 | 0.200 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2020 | 13 | 0.180 |
Why?
|
| Gallbladder Diseases | 1 | 2001 | 139 | 0.170 |
Why?
|
| Cell Transplantation | 2 | 2002 | 473 | 0.170 |
Why?
|
| Oxyphil Cells | 1 | 2020 | 55 | 0.170 |
Why?
|
| Convalescence | 1 | 2020 | 107 | 0.170 |
Why?
|
| Length of Stay | 4 | 2020 | 6486 | 0.160 |
Why?
|
| Gallbladder Neoplasms | 1 | 2001 | 190 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2003 | 475 | 0.160 |
Why?
|
| Female | 40 | 2021 | 396141 | 0.150 |
Why?
|
| Aged | 28 | 2020 | 171163 | 0.150 |
Why?
|
| Adult | 27 | 2021 | 223088 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2005 | 994 | 0.150 |
Why?
|
| Male | 35 | 2021 | 363815 | 0.150 |
Why?
|
| Middle Aged | 29 | 2020 | 223016 | 0.140 |
Why?
|
| Colectomy | 1 | 2003 | 697 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2004 | 1181 | 0.140 |
Why?
|
| Physical Exertion | 1 | 2020 | 666 | 0.140 |
Why?
|
| Retrospective Studies | 19 | 2020 | 81537 | 0.140 |
Why?
|
| Laryngeal Neoplasms | 2 | 2011 | 513 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2003 | 955 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2019 | 425 | 0.130 |
Why?
|
| Appendicitis | 1 | 2003 | 680 | 0.130 |
Why?
|
| Humans | 49 | 2022 | 765926 | 0.130 |
Why?
|
| Thyroglossal Cyst | 1 | 2015 | 31 | 0.130 |
Why?
|
| Iodine Radioisotopes | 2 | 2016 | 1029 | 0.120 |
Why?
|
| Chromium Alloys | 1 | 2015 | 71 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2010 | 20690 | 0.120 |
Why?
|
| Hematoma | 3 | 2019 | 765 | 0.120 |
Why?
|
| Elastic Modulus | 1 | 2016 | 208 | 0.120 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2016 | 150 | 0.120 |
Why?
|
| Intraoperative Period | 1 | 2016 | 510 | 0.120 |
Why?
|
| Surgicenters | 1 | 2014 | 37 | 0.120 |
Why?
|
| Ovarian Neoplasms | 2 | 2002 | 4904 | 0.120 |
Why?
|
| Malpractice | 1 | 2019 | 561 | 0.120 |
Why?
|
| Zirconium | 1 | 2015 | 109 | 0.120 |
Why?
|
| Adrenal Gland Diseases | 1 | 2015 | 141 | 0.120 |
Why?
|
| False Negative Reactions | 2 | 2007 | 570 | 0.110 |
Why?
|
| Carcinoma, Medullary | 2 | 2011 | 115 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2020 | 65194 | 0.110 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 274 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 11196 | 0.110 |
Why?
|
| Femur Head | 1 | 2015 | 295 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11858 | 0.100 |
Why?
|
| Calcinosis | 1 | 2001 | 1475 | 0.100 |
Why?
|
| Carcinoma | 2 | 2015 | 2311 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 589 | 0.100 |
Why?
|
| Otolaryngology | 1 | 2019 | 698 | 0.100 |
Why?
|
| Anti-Mullerian Hormone | 4 | 2002 | 420 | 0.100 |
Why?
|
| Tachycardia | 1 | 2014 | 598 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 95 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2019 | 2502 | 0.090 |
Why?
|
| Hypotension, Orthostatic | 1 | 2014 | 258 | 0.090 |
Why?
|
| CHO Cells | 3 | 2002 | 1372 | 0.090 |
Why?
|
| Calcitonin | 1 | 2011 | 326 | 0.090 |
Why?
|
| Neck | 3 | 2015 | 735 | 0.090 |
Why?
|
| Decision Trees | 1 | 2012 | 509 | 0.090 |
Why?
|
| Cell Nucleus Size | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cell Nucleus Shape | 1 | 2010 | 16 | 0.090 |
Why?
|
| Patient Selection | 3 | 2020 | 4248 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 735 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2010 | 15401 | 0.080 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 59496 | 0.080 |
Why?
|
| Cricetinae | 3 | 2002 | 2412 | 0.080 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 156 | 0.080 |
Why?
|
| Tracheal Neoplasms | 1 | 2010 | 124 | 0.080 |
Why?
|
| Hip Prosthesis | 1 | 2015 | 895 | 0.080 |
Why?
|
| Cell Shape | 1 | 2010 | 372 | 0.080 |
Why?
|
| Neck Dissection | 1 | 2010 | 201 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5450 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2010 | 565 | 0.080 |
Why?
|
| Drainage | 2 | 2013 | 1181 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2011 | 12973 | 0.070 |
Why?
|
| Models, Economic | 1 | 2012 | 716 | 0.070 |
Why?
|
| General Surgery | 1 | 2019 | 1722 | 0.070 |
Why?
|
| Laryngectomy | 1 | 2010 | 245 | 0.070 |
Why?
|
| Incidence | 3 | 2016 | 21513 | 0.070 |
Why?
|
| Cell Size | 1 | 2010 | 626 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 6101 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 1378 | 0.070 |
Why?
|
| Vipoma | 1 | 2006 | 7 | 0.070 |
Why?
|
| Somatostatinoma | 1 | 2006 | 10 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2002 | 2626 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 2627 | 0.060 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2006 | 88 | 0.060 |
Why?
|
| Cell Count | 1 | 2010 | 1823 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 1143 | 0.060 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2006 | 161 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 2006 | 241 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2007 | 956 | 0.060 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2006 | 258 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 1169 | 0.060 |
Why?
|
| Somatostatin | 1 | 2006 | 459 | 0.060 |
Why?
|
| Glucagon | 1 | 2006 | 533 | 0.060 |
Why?
|
| Contrast Media | 2 | 2010 | 5330 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2010 | 2243 | 0.060 |
Why?
|
| Trachea | 1 | 2010 | 1091 | 0.060 |
Why?
|
| Child | 5 | 2021 | 80568 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2010 | 1888 | 0.050 |
Why?
|
| Health Status | 1 | 2016 | 4085 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2010 | 2350 | 0.050 |
Why?
|
| Registries | 1 | 2019 | 8346 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7423 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 39228 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2002 | 2492 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 2053 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 1985 | 0.050 |
Why?
|
| Cell Division | 4 | 2003 | 4466 | 0.050 |
Why?
|
| Time Factors | 7 | 2020 | 40097 | 0.050 |
Why?
|
| Mullerian Ducts | 1 | 2002 | 203 | 0.050 |
Why?
|
| Enterocytes | 1 | 2003 | 220 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2015 | 2885 | 0.050 |
Why?
|
| Adolescent | 8 | 2020 | 88811 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2002 | 197 | 0.050 |
Why?
|
| Lipids | 1 | 2012 | 3317 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 437 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 573 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 254 | 0.050 |
Why?
|
| Jejunum | 1 | 2003 | 474 | 0.040 |
Why?
|
| Hypertension | 2 | 2014 | 8616 | 0.040 |
Why?
|
| Boston | 2 | 2003 | 9334 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2019 | 41680 | 0.040 |
Why?
|
| Endocrinology | 1 | 2005 | 441 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 3592 | 0.040 |
Why?
|
| Appendectomy | 1 | 2003 | 445 | 0.040 |
Why?
|
| Genotype | 1 | 2014 | 13026 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2011 | 3466 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2003 | 1605 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2014 | 42510 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 555 | 0.040 |
Why?
|
| Mutation | 2 | 2014 | 30192 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 2008 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2020 | 54807 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 391 | 0.040 |
Why?
|
| Membrane Glycoproteins | 3 | 2003 | 3690 | 0.040 |
Why?
|
| Patient Readmission | 2 | 2020 | 3282 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 9373 | 0.030 |
Why?
|
| Physical Examination | 1 | 2003 | 1263 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 24275 | 0.030 |
Why?
|
| Laparoscopy | 2 | 2020 | 2037 | 0.030 |
Why?
|
| Young Adult | 7 | 2020 | 59857 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2020 | 450 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2022 | 1435 | 0.030 |
Why?
|
| Prognosis | 2 | 2014 | 29890 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2002 | 3608 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 6491 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 16714 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 1227 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 20133 | 0.030 |
Why?
|
| Quality of Life | 1 | 2016 | 13463 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2020 | 1818 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2006 | 2418 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 12059 | 0.030 |
Why?
|
| Reoperation | 2 | 2015 | 4308 | 0.030 |
Why?
|
| Polyethylene | 1 | 2015 | 184 | 0.030 |
Why?
|
| Methimazole | 1 | 2013 | 41 | 0.030 |
Why?
|
| Propylthiouracil | 1 | 2013 | 68 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 4349 | 0.030 |
Why?
|
| Prostate | 1 | 2002 | 1758 | 0.030 |
Why?
|
| Antithyroid Agents | 1 | 2013 | 72 | 0.030 |
Why?
|
| Laparotomy | 1 | 2015 | 459 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2003 | 1857 | 0.030 |
Why?
|
| Polyethylenes | 1 | 2015 | 289 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 2970 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 3733 | 0.020 |
Why?
|
| Acute Disease | 1 | 2003 | 7236 | 0.020 |
Why?
|
| Breast | 1 | 2001 | 1950 | 0.020 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2011 | 40 | 0.020 |
Why?
|
| Vacuoles | 1 | 2012 | 224 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 3048 | 0.020 |
Why?
|
| Materials Testing | 1 | 2015 | 868 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1777 | 0.020 |
Why?
|
| Larynx | 1 | 2015 | 492 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 22340 | 0.020 |
Why?
|
| Metaplasia | 1 | 2011 | 325 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2013 | 254 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2011 | 336 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 74850 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 2924 | 0.020 |
Why?
|
| Seroma | 1 | 2010 | 74 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2782 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2020 | 2963 | 0.020 |
Why?
|
| Heart Failure | 1 | 2014 | 11837 | 0.020 |
Why?
|
| Mice | 5 | 2002 | 81782 | 0.020 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2011 | 249 | 0.020 |
Why?
|
| Risk | 1 | 2001 | 9599 | 0.020 |
Why?
|
| Netherlands | 1 | 2013 | 2277 | 0.020 |
Why?
|
| Immediate-Early Proteins | 2 | 2002 | 444 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2012 | 834 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2019 | 8060 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2013 | 698 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2015 | 1536 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1885 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2002 | 23597 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2015 | 2111 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 2120 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4044 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 1150 | 0.020 |
Why?
|
| Animals | 6 | 2003 | 168735 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 1491 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3447 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2015 | 1414 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 14064 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2006 | 737 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 7871 | 0.010 |
Why?
|
| Exercise | 1 | 2020 | 5936 | 0.010 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2003 | 108 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 11030 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2003 | 12768 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 6838 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 3599 | 0.010 |
Why?
|
| Anxiety | 1 | 2016 | 4669 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5873 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2002 | 265 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2003 | 1167 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 36426 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 915 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 1079 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8882 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 1546 | 0.010 |
Why?
|
| Retroviridae | 1 | 2002 | 845 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 5531 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2012 | 3241 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 855 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2006 | 1832 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13273 | 0.010 |
Why?
|
| Depression | 1 | 2016 | 8223 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2824 | 0.010 |
Why?
|
| Diabetes, Gestational | 1 | 2006 | 1263 | 0.010 |
Why?
|
| Rats | 2 | 2003 | 23708 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12822 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 22228 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 1273 | 0.010 |
Why?
|
| Polymers | 1 | 2002 | 1622 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 2778 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2002 | 7847 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 5019 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 5738 | 0.010 |
Why?
|
| Obesity | 1 | 2015 | 13082 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18382 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 4130 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 6058 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12405 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 8107 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 3684 | 0.000 |
Why?
|
| Apoptosis | 1 | 2003 | 9505 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9443 | 0.000 |
Why?
|
| United States | 1 | 2013 | 72909 | 0.000 |
Why?
|
| Pregnancy | 1 | 2006 | 30230 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36547 | 0.000 |
Why?
|